Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder
PHPSX Fund | USD 19.16 0.32 1.64% |
Slightly above 62% of Pharmaceuticals Ultrasector's investor base is looking to short. The analysis of overall sentiment of trading Pharmaceuticals Ultrasector Profund mutual fund suggests that many investors are alarmed at this time. Pharmaceuticals Ultrasector's investing sentiment can be driven by a variety of factors including economic data, Pharmaceuticals Ultrasector's earnings reports, geopolitical events, and overall market trends.
Pharmaceuticals |
Addex Therapeutics stock surged after announcing clinical candidate selection with Indivior for substance use disorder treatment. Addex could receive up to 330 million plus royalties under the agreement, while advancing its own GABAB PAM program for chronic cough.
Read at benzinga.com
![]() |
Pharmaceuticals Ultrasector Fundamental Analysis
We analyze Pharmaceuticals Ultrasector's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharmaceuticals Ultrasector using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharmaceuticals Ultrasector based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Position Weight
Cash Position Weight Comparative Analysis
Pharmaceuticals Ultrasector is currently under evaluation in cash position weight among similar funds. Percentage of fund asset invested in cash equivalents or risk-free instruments. About 40% of all global funds carry cash on their balance sheet.
Pharmaceuticals Ultrasector Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pharmaceuticals Ultrasector mutual fund to make a market-neutral strategy. Peer analysis of Pharmaceuticals Ultrasector could also be used in its relative valuation, which is a method of valuing Pharmaceuticals Ultrasector by comparing valuation metrics with similar companies.
Peers
Pharmaceuticals Ultrasector Related Equities
LGPSX | Profunds-large Cap | 0.63 | ||||
LGPIX | Large-cap Growth | 0.62 | ||||
UIPIX | Ultrashort Mid | 0.15 | ||||
TEPSX | Technology Ultrasector | 0.06 | ||||
TEPIX | Technology Ultrasector | 0.07 | ||||
SRPIX | Short Real | 0.38 | ||||
SRPSX | Short Real | 0.45 | ||||
BRPSX | Bear Profund | 0.55 | ||||
BRPIX | Bear Profund | 0.59 | ||||
UIPSX | Ultrashort Mid | 2.12 |
Other Information on Investing in Pharmaceuticals Mutual Fund
Pharmaceuticals Ultrasector financial ratios help investors to determine whether Pharmaceuticals Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharmaceuticals with respect to the benefits of owning Pharmaceuticals Ultrasector security.
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |